Literature DB >> 831872

Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis.

H M Chiu, J Hirsh, W L Yung, E Regoeczi, M Gent.   

Abstract

The relationship between the antithrombotic and anticoagulant effects of heparin was assessed using venous thrombi in rabbits. Accretion of 125I-fibrinogen onto jugular vein thrombi was used to assess the antithrombotic effect of heparin, and the protamine sulfate titration test (heparin activity) and the activated partial thromboplastin time (APTT) were used to measure its anticoagulant effect. The effect of heparin on jugular vein bleeding times was also measured in a separate group of animals. Fibrinogen accretion was significantly lower with continuous infusion than with intermittent injection. Heparin, given by continuous infusion, produced marked inhibition of fibrinogen accretion (to less than 10% of control accretion) at an APTT value of between 75 and 80 sec (control 34 sec) and at a level of heparin activity of 0.4-0.5 U/ml. Infusion of cryoprecipitate reduced the effect of heparin on the APTT relative to its effect on heparin activity. In these cryoprecipitate-treated animals, marked inhibition of fibrinogen accretion occurred at a similar level of heparin activity (0.4-0.6 U/ml) but at a significantly lower APTT (35-50 sec) than in normal animals. On the other hand, there was a progressive increase in jugular vein bleeding time with both increasing APTT values and heparin levels in both groups of animals.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 831872

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Anticoagulation and thrombolysis in children.

Authors:  M Andrew
Journal:  Tex Heart Inst J       Date:  1992

2.  Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels.

Authors:  Ramya Thota; Apar Kishor Ganti; Shanmuga Subbiah
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 3.  Considerations for analgosedation and antithrombotic management during extracorporeal life support.

Authors:  Pamela K Burcham; Alan J Rozycki; Erik E Abel
Journal:  Ann Transl Med       Date:  2017-02

4.  Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses.

Authors:  B J Darien; J Potempa; J N Moore; J Travis
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

Review 5.  Intravenous heparin dosing: patterns and variations in internists' practices.

Authors:  B M Reilly; R Raschke; S Srinivas; T Nieman
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

6.  Risk of complications during intravenous heparin therapy.

Authors:  P H Nelson; K M Moser; C Stoner; K S Moser
Journal:  West J Med       Date:  1982-03

7.  Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity.

Authors:  J G Kelton; J Hirsh; C J Carter; M R Buchanan
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

Review 8.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression.

Authors:  B A Konkle; D Ginsburg
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

10.  Establishing a new target range for unfractionated heparin for acute coronary syndromes.

Authors:  Michael S Lee; Venu Menon; Joseph Schappert; James R Wilentz; Varinder Singh; Judith S Hochman
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.